News & Insights

BioPharma's article on the biotechnology sector's notable resurgence in IPOs quotes Gunderson Boston partner Tim Ehrlich.

Gunderson Dettmer Strategic Transactions and Licensing partner Brendan McCarthy hosted the webinar “’What’s Market’ in University Licenses in the Life Sciences Industry” to discuss the key economic terms in university license agreements.

Austin-based biotechnology developer, BioReNuva, announces its newest investment from leading specialty chemical supplier for the beauty and personal care industry, The Hallstar Company

City Therapeutics, a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, announces its strategic collaboration with global eye health leader, Bausch + Lomb

Proximity-based therapeutics company, Photys Therapeutics, announces its multi-year collaboration and license agreement with Novo Nordisk

Gunderson Dettmer announces the addition of Life Sciences Partner, Adrian Rich, based in the Northern California offices

Gunderson Dettmer's Life Sciences Group participated across events during the 2024 JPM Healthcare Conference. The JP Morgan Healthcare Conference is the largest and most informative healthcare investment symposium, which connects global industry leaders, emerging fast-growth companies, innovative technology creators, and investment community members.

LMG Life Sciences recognizes Gunderson Dettmer for its market-leading support for venture-backed and public life sciences companies and the venture and growth equity funds investing in that industry around the world.